Nuformix Plc (NFX) AI Stock Analysis

• Market Cap: £4.96M
• Dividend Yield: N/A
• Average Volume (3M): 97.88M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.38
• Revenue Growth: N/A
• EPS Growth: -616.67%
• Country: UK
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,109,750,000
• 10 Day Avg. Volume: 69,476,590
• 30 Day Avg. Volume: 97,880,797
• PEG Ratio: 0.06
• Price to Book (P/B): 5.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 0.20 p ▼(-14.35% Downside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is primarily constrained by weak financial performance (no recent revenue, ongoing losses, and persistent cash burn), partially offset by a low-debt balance sheet. Technicals are modestly negative with the price below key moving averages, and valuation provides limited support due to a negative P/E and no dividend yield data.

Positive Factors

Low leverage

Zero reported debt materially reduces financial risk and preserves strategic flexibility. For a pre-revenue biotech, low leverage lengthens the time available to advance clinical or partnering milestones without immediate debt servicing pressures, improving resilience over the next several months.

Repurposing/formulation model

A strategy centered on reformulating approved drugs can shorten development timelines, lower clinical risk and cost versus de novo discovery. This business model is structurally attractive to partners and licensors and supports a sustainable path to value creation through collaborations or out-licensing.

Evidence of cost tightening

The marked reduction in the 2025 loss versus 2024 implies management actions to curb cash burn. Sustained cost discipline can materially extend runway for clinical development or partnering discussions, improving execution optionality over the coming quarters.

Negative Factors

No revenue

The absence of reported revenue across multiple years signals a stalled commercialization profile and high reliance on pipeline value or external funding. Without near-term product sales, the business must secure financing or deals to sustain operations and progress candidates.

Weak cash generation

Persistent negative operating and free cash flows create ongoing funding needs. Continued cash burn increases dilution risk or forces asset sales/partner concessions, constraining the company's ability to independently advance programs or weather trial delays in the medium term.

Shrinking equity/assets

A materially reduced equity and asset base leaves limited financial buffer for setbacks. Small balance-sheet size weakens negotiating leverage with partners and heightens solvency risk if additional funding is delayed or more capital is required to progress development milestones.

Nuformix Plc Business Overview & Revenue Model

Company Description

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

How the Company Makes Money

null

Nuformix Plc Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue is £0 in 2023–2025, profitability is consistently negative, and free cash flow remains negative (cash burn). The main offset is low financial risk from zero debt, but the equity/asset base has shrunk, reducing the financial buffer.

Income Statement

The company has not generated meaningful revenue in recent years (revenue is £0 in 2023–2025 annual reports, versus £535k in 2020), indicating a weak or stalled commercialization profile. Profitability is consistently negative, with ongoing operating losses and net losses each year (e.g., net loss of ~£0.65m in 2025 and ~£3.64m in 2024). While the 2025 loss is much smaller than 2024 (suggesting cost tightening or one-off effects), the business remains structurally loss-making and lacks a clear revenue rebound in the provided data.

Balance Sheet

Leverage is very low (total debt is £0 in 2021–2025, and modest in 2020), which reduces financial risk and provides flexibility. However, the equity base has declined materially from 2021–2023 levels to ~£0.75m in 2025, reflecting cumulative losses and/or balance sheet actions, and total assets have similarly stepped down to ~£1.02m in 2025. Overall, the balance sheet is not debt-burdened, but it appears significantly smaller and potentially more fragile than in prior years.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative every year shown (e.g., free cash flow of about -£0.61m in 2025 and -£0.33m in 2024). Cash burn fluctuates, improving in 2024 versus 2023 but worsening again in 2025, indicating limited consistency in cash discipline. With losses and ongoing cash outflows, the company likely remains dependent on external funding to sustain operations.

Breakdown	Sep 2025	Sep 2024	Mar 2023	Mar 2021	Mar 2020
Income Statement
Total Revenue	0.00	0.00	0.00	50.00K	195.55K
Gross Profit	-28.63K	0.00	-36.75K	11.33K	86.72K
EBITDA	-631.94K	-477.19K	-581.90K	-1.23M	-1.28M
Net Income	-652.59K	-3.64M	-572.98K	-1.11M	-1.25M
Balance Sheet
Total Assets	1.02M	970.54K	4.42M	4.98M	6.01M
Cash, Cash Equivalents and Short-Term Investments	97.55K	20.21K	202.55K	464.10K	1.67M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	263.92K	254.97K	222.99K	237.86K	324.62K
Stockholders Equity	754.93K	715.57K	4.20M	4.74M	5.69M
Cash Flow
Free Cash Flow	-614.61K	-331.88K	-397.49K	-1.35M	-848.83K
Operating Cash Flow	-614.61K	-331.88K	-397.49K	-1.35M	-848.22K
Investing Cash Flow	0.00	0.00	33.33K	0.00	43.72K
Financing Cash Flow	691.95K	149.54K	189.79K	139.98K	1.93M

Nuformix Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.25, and above the 200-day MA of 0.20, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.03 is Neutral, neither overbought nor oversold. The STOCH value of 3.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:NFX.

Nuformix Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£6.98M	-0.92	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCF	49 Neutral	£4.41M	-0.88	-53.79%	―	―	85.56%
HEMO	47 Neutral	£71.48M	-0.27	-3931.14%	―	―	―
IMM	46 Neutral	£27.20M	-3.00	3817.30%	―	―	―
OPTI	43 Neutral	£6.61M	-2.61	-2.42%	―	―	―
NFX	42 Neutral	£4.96M	-5.98	-153.80%	―	―	-616.67%

Nuformix Plc Corporate Events

Nuformix Raises £1m to Accelerate NXP002 Fibrosis Programme

Nuformix plc has raised £1.0 million via a placing of 500,000,000 new ordinary shares at 0.20 pence each, with the proceeds earmarked primarily to advance its NXP002 inhaled therapy for idiopathic and progressive pulmonary fibrosis and for general corporate purposes. The funding will support additional targeted pre-clinical studies designed to strengthen the NXP002 programme during ongoing out-licensing and due diligence discussions with potential large pharma and speciality partners, with the new shares expected to be admitted to trading on the London Stock Exchange on or around 17 March 2026, taking total voting rights to 2,609,749,903.

The most recent analyst rating on (GB:NFX) stock is a Sell with a £0.28 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Nuformix Wins US Orphan Drug Status for IPF Candidate NXP002

Nuformix has secured U.S. Food and Drug Administration Orphan Drug Designation for tranilast lystate, the inhaled active substance in its NXP002 programme targeting idiopathic pulmonary fibrosis, a rare and high-mortality lung disease. The designation, which follows a similar status already granted in Europe, provides development incentives such as tax credits, fee waivers and potential market exclusivity, strengthening Nuformix’s hand in ongoing licensing discussions and enhancing the programme’s strategic value for future partners.

The dual U.S. and European orphan status reinforces Nuformix’s positioning in the niche fibrosis space and could accelerate the progression of NXP002 toward clinical and commercial milestones. For stakeholders, the move underlines the company’s ability to convert its drug repurposing model into tangible regulatory assets that may improve partnering prospects and support long-term value creation, despite the programme still being at a preclinical stage.

The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.25 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass

Nuformix plc reported that all resolutions at its Annual General Meeting were passed by shareholders, confirming strong support for the company’s strategy and governance. Investors approved the annual report and remuneration, reappointed three directors and the auditor, and authorised the board to set audit fees.

Shareholders also backed authorities to allot shares, disapply pre-emption rights, buy back the company’s own shares and call general meetings on 14 days’ notice. The high approval rates across resolutions provide management with financial and operational flexibility as it advances its drug repurposing pipeline in fibrosis and oncology.

The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Nuformix Posts 2025 Annual Report and Sets Date for 2026 AGM

Nuformix plc has published its Annual Financial Report for the year ended 30 September 2025 and issued the notice for its 2026 Annual General Meeting, which will take place in London on 3 March 2026. The availability of the report and AGM documentation via the company’s website provides shareholders with updated financial and strategic information and marks a routine but important step in its corporate governance calendar as it continues to advance its preclinical pipeline in fibrosis and oncology.

The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.19 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Nuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case

In its annual results for the year to 30 September 2025, Nuformix highlighted its strategic focus on securing a business development partner for NXP002, its lead preclinical asset – a patent-protected, inhaled form of tranilast being developed as a novel treatment for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and other fibrosing interstitial lung diseases. The company reported a series of encouraging preclinical data sets showing that NXP002 can be effectively delivered to the deep lung via nebulisation, is well tolerated at high doses in vivo and ex vivo, and delivers strong anti-fibrotic and anti-inflammatory effects both as a monotherapy and in combination with current standards of care, with additive benefits that suggest action on additional disease pathways. Further studies indicated that NXP002 achieves a durable anti-inflammatory effect consistent with a twice-daily dosing profile and demonstrates a clear dose response across key fibrotic biomarkers in human lung tissue models, strengthening its positioning as a potentially differentiated inhaled therapy in a rapidly growing IPF/PPF market and supporting Nuformix’s ongoing discussions with potential licensing and development partners.